Objective:The mechanism of Yupingfeng Powder in the treatment of non-small cell lung cancer was analyzed by network pharmacology and molecular docking method.Methods:Search the related literature and TCMSP database,qu...Objective:The mechanism of Yupingfeng Powder in the treatment of non-small cell lung cancer was analyzed by network pharmacology and molecular docking method.Methods:Search the related literature and TCMSP database,query the chemical composition and action target of Yupingfeng powder,query the disease database of Genecards,OMIM,DisGeNET,Drugbank,etc.,use"non-small cell lung cancer"as the keyword to search the disease-related target,select the intersection target with Yupingfeng powder as the research target,and use Cytoscape 3.7.2 software to construct the active component-target network map.The protein-protein interaction network map was constructed by using STRING database,and the treatment core targets were further screened by topological parameters,and GO analysis and KEGG signal pathway enrichment analysis were carried out.Finally,molecular docking was verified.Results:37 active components of Yupingfeng Powder were screened,including 146 common targets and 44 core targets.GO analysis and KEGG analysis show that the core target participates in many biological processes such as angiogenesis and cell proliferation,and acts on a variety of signal pathways such as AGE-RAGE,IL-17,TNF,MAPK and so on.Molecular docking shows that the core compound has good docking activity with the target.Conclusion:Network pharmacological analysis shows that Yupingfeng powder in the treatment of non-small cell lung cancer involves multi-target and multi-pathway mechanism,and the drug and target have good docking activity,which can provide theoretical basis for follow-up experimental research.展开更多
Objective:To systematically evaluate the effect and safety of additional Yupingfeng powder combined with western medicine for the stable period of chronic obstructive pulmonary disease(COPD).Method:Databases including...Objective:To systematically evaluate the effect and safety of additional Yupingfeng powder combined with western medicine for the stable period of chronic obstructive pulmonary disease(COPD).Method:Databases including Pubmed、Web of Science、Cochrane Library、CNKI、VIP、CBM and Wanfang Data base,were searched for relevant randomized controlled trials.for Chinese and English literature about randomized controlled trials of additional Yupingfeng in the treatment of COPD on stable stage which were published from the establishment of the database to December 2019.Two researchers independently screened for,selected studies according to the inclusion and exclusion criteria and extracted data.Methodological quality was evaluated using the Cochrane Risk of Bias tool.Meta-analysis was performed using Revman 5.3 software.Results:Ninetine randomized controlled trials including 1511 patients with COPD were meta-analyzed.The total sample size was 1511.The results showed that the treatment grop with additional Yupingfeng powder could improve the clinical efficacy[OR=0.26,95%CI(0.18,0.37)],FEV1 percentage of the estimated value[MD=4.61,95%CI(2.43,6.79)],6MWD[MD=43.90,95%CI(29.48,58.32)]and patient's immunity IgA[MD=0.25,95%CI(0.17,0.34)]and can mitigate cough effectively[MD=-0.34,95%CI(-0.46,-0.23)].Conclusion:Additional Yupingfeng powder combined with routine treatment for COPD has more advantages than conventional treatment alone in improving the clinical efficacy,lung function,immune function and have less adverse events.As most of the included studies in this systematic evaluation had poor quality,the evidence to support conclusion was weak,so it was necessary to conduct more multi-center clinical trials with high quality methods and rigorous design.展开更多
Yupingfeng Powder is widely used in the treatment of respiratory,digestive,urinary,dermatological and ENT diseases.The author reviewed the animal pharmacology experiments and clinical cases in recent years,and summari...Yupingfeng Powder is widely used in the treatment of respiratory,digestive,urinary,dermatological and ENT diseases.The author reviewed the animal pharmacology experiments and clinical cases in recent years,and summarized and analyzed the diseases he treated,providing ideas and methods for clinical users.展开更多
Objective:To use Meta-analysis to evaluate the effectiveness and safety of Yupingfeng Powder(YPFP)in regulating the immune function of patients with chronic obstructive pulmonary disease.Methods:Computers were used to...Objective:To use Meta-analysis to evaluate the effectiveness and safety of Yupingfeng Powder(YPFP)in regulating the immune function of patients with chronic obstructive pulmonary disease.Methods:Computers were used to search databases such as China National Knowledge Infrastructure(CNKI),VIP Database,China Biology Medicine disc(CBMdisc),Wanfang Database,PubMed,Cochrane Library,etc.Search all randomized controlled trials(RCTs)of YPFP in the treatment of stable chronic obstructive pulmonary disease,with CD4,CD8,CD4/CD8,IgE,IgA,IgM,and IgG as the outcome indicators.Two reviewers independently conducted literature search,conducted literature quality evaluation with the risk bias assessment tool recommended by Cochrane Handbook,and conducted data extraction,discussed and resolved disputes,and used RevMan 5.3 software for Meta-analysis.Results:A total of 11 randomized controlled trials with 1,058 patients were included.According to the Meta-analysis,the results of the effectiveness analysis showed that after oral administration of YPFP in the stable phase of chronic obstructive pulmonary disease,the test group CD3,CD4,CD8,CD4/CD8,IgA,IgE,IgM,IgG8 were better than the control group(P<0.05).Conclusion:Oral administration of YPFP in the stable period of chronic obstructive pulmonary disease can effectively regulate the immunity.However,the number of studies included in this study is small and the heterogeneity is large,and it is still necessary to design high-quality clinical trials for in-depth research.展开更多
基金Priority Theme Setting of Traditional Chinese Medicine for Malignant Tumor and Implementation Scheme Design of Evidence-based Research(No.K-858)Beijing Municipal Commission of Science and Technology(No.D161100005116001)。
文摘Objective:The mechanism of Yupingfeng Powder in the treatment of non-small cell lung cancer was analyzed by network pharmacology and molecular docking method.Methods:Search the related literature and TCMSP database,query the chemical composition and action target of Yupingfeng powder,query the disease database of Genecards,OMIM,DisGeNET,Drugbank,etc.,use"non-small cell lung cancer"as the keyword to search the disease-related target,select the intersection target with Yupingfeng powder as the research target,and use Cytoscape 3.7.2 software to construct the active component-target network map.The protein-protein interaction network map was constructed by using STRING database,and the treatment core targets were further screened by topological parameters,and GO analysis and KEGG signal pathway enrichment analysis were carried out.Finally,molecular docking was verified.Results:37 active components of Yupingfeng Powder were screened,including 146 common targets and 44 core targets.GO analysis and KEGG analysis show that the core target participates in many biological processes such as angiogenesis and cell proliferation,and acts on a variety of signal pathways such as AGE-RAGE,IL-17,TNF,MAPK and so on.Molecular docking shows that the core compound has good docking activity with the target.Conclusion:Network pharmacological analysis shows that Yupingfeng powder in the treatment of non-small cell lung cancer involves multi-target and multi-pathway mechanism,and the drug and target have good docking activity,which can provide theoretical basis for follow-up experimental research.
基金National Science and Technology Major Projects of Sudden Severe Acute Respiratory Infectious Diseases Treatment New Technology research and the New Scheme(No.2017 zx10204401)。
文摘Objective:To systematically evaluate the effect and safety of additional Yupingfeng powder combined with western medicine for the stable period of chronic obstructive pulmonary disease(COPD).Method:Databases including Pubmed、Web of Science、Cochrane Library、CNKI、VIP、CBM and Wanfang Data base,were searched for relevant randomized controlled trials.for Chinese and English literature about randomized controlled trials of additional Yupingfeng in the treatment of COPD on stable stage which were published from the establishment of the database to December 2019.Two researchers independently screened for,selected studies according to the inclusion and exclusion criteria and extracted data.Methodological quality was evaluated using the Cochrane Risk of Bias tool.Meta-analysis was performed using Revman 5.3 software.Results:Ninetine randomized controlled trials including 1511 patients with COPD were meta-analyzed.The total sample size was 1511.The results showed that the treatment grop with additional Yupingfeng powder could improve the clinical efficacy[OR=0.26,95%CI(0.18,0.37)],FEV1 percentage of the estimated value[MD=4.61,95%CI(2.43,6.79)],6MWD[MD=43.90,95%CI(29.48,58.32)]and patient's immunity IgA[MD=0.25,95%CI(0.17,0.34)]and can mitigate cough effectively[MD=-0.34,95%CI(-0.46,-0.23)].Conclusion:Additional Yupingfeng powder combined with routine treatment for COPD has more advantages than conventional treatment alone in improving the clinical efficacy,lung function,immune function and have less adverse events.As most of the included studies in this systematic evaluation had poor quality,the evidence to support conclusion was weak,so it was necessary to conduct more multi-center clinical trials with high quality methods and rigorous design.
基金Granted by the Guangdong Provincial Bureau of Traditional Chinese Medicine(No.:20131155).
文摘Yupingfeng Powder is widely used in the treatment of respiratory,digestive,urinary,dermatological and ENT diseases.The author reviewed the animal pharmacology experiments and clinical cases in recent years,and summarized and analyzed the diseases he treated,providing ideas and methods for clinical users.
基金This research was supported by the Tianjin Health Commission,Tianjin Administration of Traditional Chinese Medicine-Traditional Chinese Medicine,and Integrated Traditional Chinese and Western Medicine Scientific Research Projects(No.2019031).
文摘Objective:To use Meta-analysis to evaluate the effectiveness and safety of Yupingfeng Powder(YPFP)in regulating the immune function of patients with chronic obstructive pulmonary disease.Methods:Computers were used to search databases such as China National Knowledge Infrastructure(CNKI),VIP Database,China Biology Medicine disc(CBMdisc),Wanfang Database,PubMed,Cochrane Library,etc.Search all randomized controlled trials(RCTs)of YPFP in the treatment of stable chronic obstructive pulmonary disease,with CD4,CD8,CD4/CD8,IgE,IgA,IgM,and IgG as the outcome indicators.Two reviewers independently conducted literature search,conducted literature quality evaluation with the risk bias assessment tool recommended by Cochrane Handbook,and conducted data extraction,discussed and resolved disputes,and used RevMan 5.3 software for Meta-analysis.Results:A total of 11 randomized controlled trials with 1,058 patients were included.According to the Meta-analysis,the results of the effectiveness analysis showed that after oral administration of YPFP in the stable phase of chronic obstructive pulmonary disease,the test group CD3,CD4,CD8,CD4/CD8,IgA,IgE,IgM,IgG8 were better than the control group(P<0.05).Conclusion:Oral administration of YPFP in the stable period of chronic obstructive pulmonary disease can effectively regulate the immunity.However,the number of studies included in this study is small and the heterogeneity is large,and it is still necessary to design high-quality clinical trials for in-depth research.
